ClinicalTrials.gg
Enrolling by invitationNCT03044847Updated Jul 29, 2021

The Cohort Study for Chronic Obstructive Pulmonary Disease (COPD) in China

An observational study in Pulmonary Disease, Chronic Obstructive, sponsored by Beijing Chao Yang Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-29.

Sponsored by Beijing Chao Yang Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,800
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital — 6 open to participants now, 6 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Beijing Chao Yang Hospital.

Started
2016
the only one that year
Observational
7 of 13
5 open now
Registered
6th of 13
by date

Among the 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital, this one is the only one that started in 2016, is one of 7 observational ones, and was the 6th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

6 of the 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to establish the large COPD cohort and biological database in China, aiming for precision medicine to optimize diagnosis and treatment choices and to monitor and improve clinical outcomes in this disease.

Read the detailed description

This is a 5-year multi-center observational prospective longitudinal cohort study to to establish the large COPD cohort and biological database in China, including COPD subjects( n= 3000) and GOLD 0 subjects (n= 800).Sites Investigators will be respiratory physicians working in the respiratory department of our sites, which must be tier 2 or tier 3 hospitals in China, with the equipment and ability to conduct pulmonary function test, HRCT.Patients must meet all the inclusion criteria and none of the exclusion criteria.No additional investigational drugs will be applied to the patients. Full analysis set will be used for all analyses. Missing data will be analysed as it is. Statistical analysis will be conducted by epidemiology \& statistics work group from Chinese Academy of Sciences, using SAS and SUDAAN software. An electronic data capture system will be used in this study. Paper-based questionnaire administration will also be used.Questionnaire variables will be checked before data entry.During the study, PI will be in charge of the monitoring of the whole procedure. Two working group will do the data cleaning and data analysing.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Tier 2 or tier 3 hospitals in China

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 40-75 years
  • group: baseline post-bronchodilator /FVC \< 0.7
  • GOLD 0 group: individuals with chronic respiratory symptoms and/or high risk factors
  • Signed obtained prior to participations with the ability to comply with protocol and be available for study visits over 5 years

Exclusion criteria

Exclusion Criteria:

  • Acute exacerbation in the past 3 months
  • Having other respiratory diseases with massive lung tissue destruction such as severe bronchiectasis and tuberculosis, etc
  • The usual criteria of serious uncontrolled diseases
  • thoracic or abdominal surgery in the last 3 months
  • eye surgery in the last three months
  • retinal detachment
  • myocardial infarction in the last 3 months
  • admission to hospital for any cardiac condition in the last month
  • heart rate over 120 beats per minute
  • antibacterial chemotherapy for tuberculosis
  • pregnant or breast feeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,800 participants (estimated)
Patient registry
No

Groups and cohorts

  • COPD group

    The post-bronchodilator FEV1/FVC ratio \< 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease

    Other: COPD group

  • GOLD 0 group

    GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.

Interventions

  • OtherCOPD group

    The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.

06

What researchers measure

Primary outcomes

  1. COPD-related mortality and all-cause mortality

    COPD-related mortality and all-cause mortality

    Time frame: 10 years

Secondary outcomes

  1. COPD exacerbation rate per year

    COPD exacerbation rate per year

    Time frame: 10 years

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — no plan to share IPD

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Dec 2028 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2017
First posted
Feb 7, 2017
Start
Jul 2016
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Jul 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03044847
Responsible party
Kewu Huang (Professor/M.D., Beijing Chao Yang Hospital) — Principal investigator
First posted
Feb 7, 2017
Start date
Jul 2016
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 29, 2021

Study contacts

Kewu Huang, M.D.
study director · Beijing Chao Yang Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion